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The recent discovery ofmicroRNAs (miRNAs)hasintroduced anewlayer ofcomplexity to the process ofgeneregulation. MiRNAs
are essential for cellular function, and their dysregulation often results in disease. Study of miRNA expression and function in
animal models and human lymphomas has improved our knowledge of the pathogenesis of this heterogeneous disease. In this
paper, we attempt to describe the expression of miRNAs and their function in lymphomas and discuss potential miRNA-based
therapies in the diagnosis and treatment of lymphomas.
1.Introduction
Recently, a class of noncoding RNAs called miRNAs has
emerged as critical gene regulators in cell growth, dis-
ease, and development. MiRNAs are 18–24 nucleotide
long noncoding RNAs, which regulate gene expression
by pairing with 3  untranslated region (UTR) of target
mRNA and inhibiting protein translation and/or inducing
mRNAdegradation.MiRNAsmodulate criticalcellprocesses
including cell growth, development, and diﬀerentiation.
MiRNAs constitute approximately 1–3% of the genome and
are predicted to regulate 30% of human genes. Currently,
there are 940miRNAs identiﬁed in humans and 590 in
mice based on evolutionary conservation (miRBase 15,
http://www.mirbase.org/). MiRNAs are transcribed by RNA
polymerase II as long primary transcripts (pri-miRNA),
which are processed into ∼70 nucleotide long precursor
miRNAs (pre-miR) by an RNAse-III-like enzyme, Drosha,
together with DGCR8 (DiGeorge syndrome critical region
gene 8), an RNA binding protein in the nucleus [1, 2].
Export of pre-miR to cytoplasm is mediated by Exportin-
5 via GTP-dependent export, where it is further cleaved
b ya n o t h e rR N A s e - I I Ie n z y m e ,c a l l e dD i c e r ,i n t oam a t u r e
dsRNA duplex. After strand-selection mature miRNA is
assembled into the RNA-induced silencing complex (RISC),
it ultimately performs regulatory function [3].
MiRNA-mRNA interactions are characterized by perfect
or nearly perfect Watson-Crick base pairing involving 5 
miRNA seed region (typically bases 2–8) that binds the
target mRNA [4]. A single miRNA is predicted to target
about 300mRNAs just as a single mRNA can be targeted
by multiple miRNAs. mRNA targets for speciﬁc miRNA
can be predicted by bioinformatics’ algorithms (Targetscan,
Pictar, Miranda), but validation must be achieved through
luciferase reporter assays, quantitative real-time PCR, and
immunoblotting.
In addition to the canonical mechanisms of miRNA gene
regulation through 3  UTR interactions, other “noncanon-
ical” miRNA-mediated mechanisms of mRNA expression
m o d u l a t i o na r ee m e r g i n g( r e v i e w e di nG a r z o ne ta l .[ 5]).
Some miRNAs have been shown to bind to the open reading
frame or tothe5  UTR of thetarget genesand, in some cases,
activate rather than inhibit gene expression [5]. Our group
has recently reported that miRNAsexhibit decoy activity and2 Advances in Hematology
bind to ribonucleoproteins in a seed sequence and an RISC-
independent manner and interfere with their RNA binding
functions [5]. Few studies have reported that miRNAs can
also regulate gene expression at the transcriptional level by
binding directly to the DNA [5]. Overall, these data show
thecomplexityand widespread regulation ofgeneexpression
by miRNAs that should be taken into consideration when
developing miRNA-based therapies.
Analysis of miRNA localization in the genome by
Rodriguez et al. [6] yielded useful information into their
mode of transcription. Based on their location, miRNAs can
be intergenic, intronic, or exonic and can be transcribed as
a single miRNA from its own promoter, (monocistronic)
or several miRNAs as a cluster from a shared promoter,
(polycistronic). Intergenic miRNAs are found in between
genesin distinct transcription units. miRNAscan be intronic
ofcodingornoncodinggenes,wheretheymaybetranscribed
from the same promoter as the host gene. The exonic
miRNAs are rare and are mainly found in exons of coding
or noncoding genes. A study from our lab showed that in
mouse, miRNA genes are frequently located near cancer
susceptibility loci, which are often subjected to genomic
alterations leading to activation by translocations or ampli-
ﬁcations, or loss of function due to deletions, insertions, or
mutations [7].
In addition to the above structural genetic alterations,
various epigenetic events can also lead to miRNA expression
deregulation. miRNA promoter hypermethylation and/or
histone hypoacetylation has been described in solid tumors
and hematological malignancies [8–10]. Furthermore, treat-
ment with methylating agents or histone deacetylases
inhibitor drugs leads to activation of tumor suppressor
miRNAs like miR-127 which targets proto-oncogene BCL6
in human bladder cancer cells [8]. Aberrant miRNA expres-
sion may also result from downstream miRNA processing.
For example, short hairpin-mediated silencing of Dicer
and Drosha (RNAses involved in miRNA processing) can
lead to global repression of miRNA expression promoting
cellular transformation and tumorigenesis in vivo [11].
Finally, miRNA activation can also result from increased
transcriptionfromtheirrespectivehostgenesduetoaberrant
transcription factor activity. For example, activation of miR-
34a, miR-34b,a n dmiR-34c family of miRNAs by tumor sup-
pressor p53 may in part contribute to its tumor suppression
activity [12, 13].
Deregulated miRNA expression is reported in various
human diseases including lymphomas, suggesting an impor-
tant role in their pathogenesis. Animal studies have estab-
lished that a subset of miRNAs play a role in the initiation
and progression of lymphomas. The purpose of this paper is
to synthesize the current work on miRNA proﬁling of lym-
phomas in light of developingmiRNA therapeutic strategies.
The potential implications for prognosis and possible uses
in diagnosis and treatment are also discussed. Two of the
most notoriousmiRNAsupregulated in various lymphomas,
miR-155 and miR-17∼92, are discussed in detail, since
these miRNAs are among the best studied owing to the
availability of both gain- and loss-of-function mouse
models.
1.1. miRNAs in Lymphomas: miRNA-155. The original miR-
155 was encoded from a common retroviral integration site
in avian leukosis virus-(ALV-) induced B-cell lymphomas,
called bic for B-cell integration cluster and later shown to
cooperate with c-MYC to induce lymphomagenesis [14].
Earlier studies showed miR-155 was upregulated in pediatric
Burkitt’s lymphoma [15], aggressive activated B-cell-like
(ABC) subtype of DLBCL [16], primary mediastinal B-
cell lymphoma (PMBL) and Hodgkin’s lymphoma [17],
and CLL [18]. Since miR-155 is frequently upregulated in
B-cell lymphoproliferative disorders, Carlo Croce’s group
developed transgenic mice that overexpress miR-155 in
B cells under the Eμ promoter. These mice were viable
and fertile but developed a polyclonal lymphoproliferative
disorder followed by pre-B-leukemia/lymphoma at a young
age. This was the ﬁrst evidence that a single miRNA
deregulation could cause cancer [19]. The oncogenic
nature of this miRNA was reinforced by identiﬁca-
tion of miR-155 orthologue (miR-K12-11) in the Kaposi
sarcoma-associated herpesvirus (KSHV) associated with
B-cell tumors [20], and recently from Marek’s disease
virus of chickens [21]. The mechanisms involved in miR-
155 induced lymphomagenesis are still under extensive
investigation. However, two independent studies recently
indicate that miR-155 represses SH2-domain contain-
ing inositol-5-phosphatase-1 (SHIP-1), which is a critical
phosphatase that negatively downmodulates AKT path-
way and has functions during normal B-cell develop-
ment [22]. Thus, sustained overexpression of miR-155 in
B cells unblocks AKT activity, inducing B-cell proliferation.
Similar results were reported in the myeloid cells, resulting
from myeloproliferation in mice transplanted with miR-155
transduced murine bone marrow HSCs [23]. Hematopoietic
reconstitution assays showed extensive myeloproliferation
with associated splenomegaly and morphological dysplastic
changes. In addition to SHIP-1, C/EBPβ,P U . 1 ,a n dC S F R
are also validated miR-155 targets. Physiologically, miR-
155 is upregulated during B-cell activation in the germinal
centers upon antigen stimulation and hence plays a role
in antibody class switching and plasma cell formation, both
of which are impaired in the miR-155-deﬁcient mice [24,
25]. In another study, miR-155/BIC was transcriptionally
regulated during normal B cell receptor activation through
the AP-1 transcription factor and extracellular signaling-
regulated kinase (ERK) and c-Jun N-terminal kinase JNK
pathways [26]. Above ﬁndings show critical role of miR-
155 in immune cell development, diﬀerentiation, function,
andimmuneresponseregulation,dysregulationofwhich can
lead to malignancies like lymphoma.
1.2. miRNAs in Lymphomas: miR-17∼92. Another miRNA
which is reported to have a major role in lymphomagenesis
is the miR-17∼92 polycistron located in 13q31-32, a region
commonly ampliﬁed in B-cell lymphomas and upregulated
in 65% of the B-cell lymphoma patients [27, 28]. The miR-
17∼92 cluster consists of miR-17, 18a, 19a, 19b-1, 20a,a n d
92a-1 and is encoded from the last exon of noncoding
RNA called C13orf25. The cluster has two paralogs inAdvances in Hematology 3
the genome, miR-106a∼363 on chromosome X in mice
and humans consisting of six miRNAs, and miR-106b∼25
on chromosome 5 in mice (chromosome 7 in humans)
consisting of three miRNAs encoded from the 13th intron
of the DNA-replication gene Mcm7 [29].
Gain and loss-of-function studies of miR-17∼92 poly-
cistron have provided an important insight into its mech-
anism of action and its targets. He et al. demonstrated
that virus-mediated overexpression of miR-17∼92 in lym-
phocytes of eμ-MYC (B-cell) transgenic mice accelerated
tumor development [28]. O’Donnell et al. simultaneously
reportedthatMYCbindsandactivatesexpressionofthemiR-
17∼92 cluster [30]. Two members of the polycistron, miR-
17-5p and miR-20a, downregulate E2F1, which is a direct
target of MYC that promotes cell cycle progression. More
recently, Xiao and colleagues [31] reported that mice with
sustained expression of miR-17∼92 in lymphocytes exhibit a
lymphoproliferative disorder, autoimmunity, and premature
death. These mice have decreased levels of the proapoptotic
BIM and the tumor suppressor PTEN. Both genes were
further conﬁrmed as targets of the miR-17∼92 polycistron
members [31]. Ventura et al. [29] conﬁrmed these ﬁndings
and showed that targeted deletion of miR-17∼92 polycistron
(but not its paralogs) in mice is embryonically lethal and
critical for lung and B-cell development. In particular, these
mice exhibited a block in B-cell diﬀerentiation at the pro-B
to pre-B transition caused by high levels of the proapoptotic
protein BIM. These experiments suggest that the miR-17∼92
cluster acts speciﬁcally during the transition from pro-B to
pre-B lymphocyte development, enhancing the survival of
the B-cells at this stage by targeting the proapoptotic BIM.
Further dissection of the genetic complexity of the cluster
wasdemonstratedbygeneratingconditionalknockoutalleles
of the four seed regions represented in the cluster: miR-
17, miR-20a; miR-18a; miR-19a, miR-19b-1; miR-92-1 [32].
Mu and colleagues [32] found that deletion of the whole
miR-17∼92 cluster slows c-Myc-induced oncogenesis. This
phenotype was rescued by reintroduction of the full cluster,
but not by the cluster lacking miR-19a and miR-19b,t h e r e b y
suggesting miR-19 as the most important miRNA of the
cluster. Using a diﬀerent approach, Olive and colleagues
[33] overexpressed individual miRNAs in the Eμ-MYC mice
model. They found that overexpression of the whole cluster,
without miR-92,b u tn o tt h emiR-19a or miR-19b,p r o m o t e s
oncogenesis. In summary, both studies indicate that miR-
19 is critical for the oncogenic activities of this cluster.
Recently, miR-17∼92 was also shown to downregulate TGFβ
signaling pathway leading to clusterin downregulation and
hence stimulating angiogenesis and tumor cell growth in
glioblastomas [34].
2.Micro-RNA ExpressionProﬁlingStudies
Strong experimental data supported a critical role for
miRNAsin lymphomagenesis; severalgroups performed sys-
tematicmiRNAproﬁlinginlymphomapatientsamplesusing
avariety ofmiRNAexpression platforms. Wewill summarize
the miRNA expression data in lymphoma according to the
two main categories: Hodgkin lymphoma (HL) and non-
Hodgkin lymphoma (NHL) along with its subcategories.
2.1.HodgkinLymphoma. Hodgkinlymphoma(HL)isoneof
the most curable forms of cancer, common in younger peo-
ple and is characterized by the presence of Hodgkin/Reed-
Sternberg (HRS) cells. HL is derived from mature B cells
and subdivided into classical Hodgkin lymphoma (cHL)
and nodular lymphocyte predominant Hodgkin lymphoma
(NLPHL).HLisuniqueamong B-celllymphomasbecause of
the rarity of the lymphoma cells, called HRS cells in cHL and
lymphocyte predominant (LP) cells in NLPHL, which makes
upto0.1%to10%ofthecellsintheaﬀectedtissues[35].The
HRS cells are characterized by the loss of B-cell speciﬁc gene
expression, and these cells show constitutive NF-κBa c t i v i t y ,
which may be responsible for their enhanced survival [35].
The most common form of HL is the classical Hodgkin
lymphoma (cHL) and represents scarcity of tumor cells in
lymphoma biopsies, which limits the genetic analysis of HRS
cells [36]. Comparison of miRNA expression of microdis-
sected HRS cells from cHL patients to CD77+ GC B cells
showed three downregulated miRNAs, namely, miR-520a,
miR- 200a,a n dmiR-614 and twelve upregulated miRNAs,
namely,miR-20a, miR-21, miR-9, miR-155,miR-16, miR-140,
miR-18a, miR-30b, miR-30a-5p, miR-196a, miR-374,a n d
miR-186 [36]. The functional implications of these results
are still to be investigated, but some of the most common
predicted targetsof the upregulated miRNAsare members of
the SOCS (Suppressor of Cytokine signaling) family which
may contribute to activated JAK/STAT signaling in the HRS
cells due to miRNA-mediated SOCS inactivation. Studies
from HL cell lines showed miR-9 to be one of the ten most
signiﬁcantly upregulated miRNAs and target B-lymphocyte-
induced maturity protein 1 (Blimp1 orPRDM1) which plays
an important role in plasma cell diﬀerentiation [37].
miRNA proﬁling study from 49cHL patient samples
and 10 reactive lymph nodes (RLNs) using real time PCR
revealed three distinct disease groups: nodular sclerosis cHL,
mixed cellularity cHL, and RLNs, signifying the role of
miRNAs in predicting prognosis [38]. HL-speciﬁc miRNA
signature from HL cell lines includes miR-17∼92, miR-16,
miR-21, miR-24,a n dmiR-155 being upregulated and miR-
150 as the only downregulated miRNA [39]. About 40–60%
of HL patients have EBV (Epstein Bar Virus) associated
with the malignant cells, but precise role of EBV in cHL
pathogenesis is unknown [38]. Complex interactions among
v i r a la n dh o s tm i R N A sc a nc o n t r i b u t et ol y m p h o m a g e n e s i s
by targeting multiple pathways. EBV was shown to inﬂuence
miRNA in cHL with 10 host miRNAs diﬀerentially expressed
in EBV+ and EBV− cases [38]. It is hypothesized that EBV
can lead to NF-κB activation responsible for survival of HRS
cell [40]. Previously, EBV has been shown to transactivate
miR-155 through NF-κB activation and hence may be an
important pathogenesis event in cHL [41]. The miRNA that
seems critical for the survival advantage of cHL cells is miR-
21 which can indirectly upregulate antiapoptotic genes [38].
The diﬀerences in miRNA expression proﬁle of HRS cell
by Van Vlierberghe et al. [36] and primary cHL patient4 Advances in Hematology
samplesand HLcelllinesbyGibcusetal.[39]an dN a varr oet
al. [38] highlight the disparity between the expression proﬁle
ofthetumorousHRScellandthenonneoplasticsurrounding
cells. It also signiﬁes the intricate interaction between the
HRS cell and the surrounding microenvironment, which is
important in understanding the disease biology.
2.2. Non-Hodgkin Lymphoma. NHL is an increasingly com-
mon cancer with over 60,000 cases every year in the US
and includes more than 20 lymphoproliferative malignant
diseases that originate from T and B lymphocytes and which
can be aggressive (fast growing) or indolent (slow growing).
B-cell NHLs include diﬀuse large B-cell lymphoma, mantle
cell lymphoma, Burkitt’s lymphoma, follicular lymphoma,
and rare lymphomas. Still other categories include chronic
lymphocytic leukemia/lymphoma, immunoblastic large cell
lymphoma, and precursor B-lymphoblastic lymphoma. T-
cell NHLs include mycosis fungoides, anaplastic large
cell lymphoma, and precursor T-lymphoblastic lymphoma.
Based on the cell of origin and degree of diﬀerentiation,
various subcategories of non-Hodgkin lymphoma have been
established according to the 2008 classiﬁcation of tumors
of hematopoietic and lymphoid tissues by World Health
Organization. miRNA proﬁling studies available in the
literature for selected are discussed.
2.2.1. Diﬀuse Large B-Cell Lymphoma (DLBCL). DLBCL
is the most common type of NHL that represents over
one-third of new diagnoses (∼20,000 new cases per year)
[42]. Gene expression proﬁling has been used to classify it
into three major histologically indistinguishable subgroups:
germinal center B-cell-like DLBCL (GCB-DLBCL), activated
B-cell-like (ABC-DLBCL), and primary mediastinal DLBCL
(PMBCL) [43]. This subclassiﬁcation is also achieved by
immunostaining for CD10, BCL6, and MUM-1 [44]a n d
has been incorporated in the 2008 World Health Organi-
zation classiﬁcation of lymphoid tumors [45]. The three
subgroups have diﬀerent clinical outcomes with respect to
the treatment regimen (CHOP and R-CHOP) with a 5-
year survival rates of 59%, 30%, and 64% in patients with
GCB-DLBCL, ABC-DLBCL, and PMBCL, respectively [46].
From the cytogenetics point of view, GCB lymphomas are
characterized by t(14;18) translocation, deletion of tumor
suppressor PTEN, and ampliﬁcation of micro-RNA cluster
miR-17∼92 and p53 mutations [47]. ABC lymphomas are
known for antiapoptotic BCL2 ampliﬁcation, and majority
of them have deletion of tumor suppressor loci like INK4-
ARF which encodes p16, an inhibitor of senescence and
p14ARF, an inhibitor of p53 activation [47]. Loss of these
tumor suppressors contributes to poor prognosis and resis-
tance to chemotherapy in ABC type of lymphomas. PMBL
(Primary mediastinal B-cell lymphoma) is characterized by
ampliﬁcation of 9p24 region of chromosome 9 in half
of the patients with this subtype and also in Hodgkin
lymphoma. This region encompasses many megabases of
DNA,butonemajor candidateis JAK2,a tyrosine kinase that
phosphorylates and activates the transcription factor STAT6.
Furthermore, SOCS1 (suppressor of cytokine signaling),
targetofmiR-155 isregularlydeletedinPMBLandHodgkin’s
lymphoma.
Recently, miRNA expression proﬁling studies have been
shown to successfully classify DLBCL into it subcategories as
deﬁned by mRNA and immunohistochemistry. A 9-miRNA
signature(hsa-miR-146b-5p, hsa-miR-146a, hsa-miR-21, hsa-
miR-155, hsa-miR-500, hsa-miR-222, hsa-miR-363, hsa-miR-
574-3p,a n dhsa-miR-574-5p) from study by Malumbres et
al. [48] can precisely diﬀerentiate the DLBCL into ABC or
GCB subtypes, and expression of some of these miRNAs
correlated with clinical outcome. It was also shown that
during normal B-cell development, miR-125b is enriched
in GC B cells and keeps IRF4 and PRDM1/Blimp1 down
and miR-223 is enriched in memory B cells where it targets
and downregulates LMO2 [48]. The reciprocal relationship
between miRNAs and their targets in these cells signiﬁes
the physiological relevance whereby downregulation of IRF4
and PRDM1 in GC B-cells is essential for progression of
these cellsto memory (post GC)B cellswhich downregulates
LMO2 and upregulates IRF4and PRDM1.Interestingly, they
also came up with a 39 miRNA signature which can suc-
cessfully diﬀerentiate between distinct B-cell subpopulations
comprising the “cell-of-origin classiﬁer.”
Unique categorization of 86 DLBCLs was reported
by genome wide miRNA expression proﬁling into three
subtypes, namely, MiRNA Group/MG-A, B, and C [49].
The new classiﬁcation is unrelated to already known GCB
and non-GCB classiﬁcations. Distinctive miRNA signatures
obtained using unsupervised hierarchical clustering could
distinguish these three groups based on just 16 miRNAs
with miR-17∼92 cluster members (miR-17-5p, miR-17-3p,
miR-18a, miR-19a, miR-20a, miR-20b,a n dmiR-92)a n di t s
paralog miR-106a, being the predominant one in addition
to miR-29a/c,miR-100, miR-199a∗, miR-140, miR-630,a n d
miR-16 [49].Furthermore,patientswiththeMG-Asignature
characterized by upregulation of the miR-17∼92 cluster and
its paralog miR-106a-363 of chromosome X had the worst
overall survival. This miRNA signature-based classiﬁcation
of DLBCL highlights a signiﬁcant role of MYC as, unlike
the miR-17∼92,w h i c hi sa c t i v a t e db yM Y C[ 30], 95% of the
miRNAs which are suppressed by MYC were signiﬁcantly
downregulated in the MG-A subgroup and overexpressed
in the MG-C [49]. In addition, integration of copy number
and expression data in these samples showed overexpression
of miR-100, miR-125b-1, and miR-130a (on chromosome
11, and members of the MG-B cluster) as a consequence
of chromosomal gain or ampliﬁcation [49]. However, no
copy number loss at chromosome 13q14 inﬂuenced the
expression of miR-15a/16-1, loss of which is often attributed
to common B-cell malignancies like CLL [49, 50]. This
study also uncovered a novel set of miRNAs like miR-222
and let-7f (associated with other malignancies), miR-513
and miR-223 (linked to immune regulation and related B-
cell tumors), miR-424 (hematopoiesis), and miR-188 and
miR-374 (no known physiological or pathological functions)
[49]. Interestingly, several of these miRNA loci map to
chromosome X, but the fact that no candidate target genes
in this region have been ascribed to any copy number
changes in DLBCL leads to the signiﬁcance of the roleAdvances in Hematology 5
BCL6 Apoptosis, DNA damage response
BCL2, CCND2, CCND3,
CCNE, CDK4, CDK6
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IRF4, PRDM1/Blimp1
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Targets Cellular processes Tumor suppressor miRs
OncomiRs
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miR-15a-16
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miR-125b
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Figure 1: Tumor suppressor miRNAs and oncomiRsin DLBCL and their target genes implicated in various processes involved in malignant
transformation.
Table 1: miRs as associated with disease outcome.
Poor prognosis Favorable outcome Reference
Non-Hodgkin lymphoma
DLBCL miR-127, miR-222 [48, 51]
miR-637, miR-608, miR-302
miR-330, miR-30e, miR-425,
miR-27a, miR-24, miR-23a,
miR-199b, miR-199a∗, miR-100
[56]
BL miR-155
MCL miR-29, miR-20b [57, 58]
Hodgkin lymphoma
HL miR-21 [38]
TCL, SzS miR-125 [59]
of miRNA deregulation in this disease [49]. It is worth
mentioning that Li et al. [49] provide an important miRNA
expression signature of DLBCL, linked to copy number
changes targeting the miRNA genome, MYC activity, and
is unrelated to the initially established cell-of-origin clas-
siﬁcation. miRNA signature associated with event-free and
overall survival in DLBCL was reported to include: miR-21,
miR-127, miR-34a, miR-195,a n dmiR-let7g [51].Inaddition,
few lymphoma-speciﬁc miRNA signature included miR-150,
miR-17-5p, miR-145, miR-328,a n do t h e r s[ 51]. One of the
most commonly deregulated miRNAs in DLBCL is miR-
155, and some of its validated targets, which have role in B-
cell homeostasis, include PU.1, AID, and SOCS1. In another
study miR-155 overexpression was shown to make DLBCLs
resistant to the growth-inhibitory eﬀects of both TGFβ1a n d
bone morphogenetic protein (BMP), via defective induction
of p21 and impaired cell cycle arrest through targeting
SMAD5 [52]. Genomic proﬁling of Richter’s syndrome,
which represents a transformation of chronic lymphocytic
leukemia (CLL) to aggressive lymphoma and is mostly rep-
resented by DLBCL, with a postgerminal center phenotype,
shows a 13q ampliﬁcation which encodes the miR-17∼92
cluster which interacts with c-MYC [53]. Since DLBCL can
be considered as a prototype of human lymphomas, role of
miRNAs and their respective targets in lymphomagenesis is
depicted in Figure 1.
2.2.2. Mantle Cell Lymphoma(MCL). Mantle celllymphoma
(MCL) is a subtype of NHL which usually arises due to
malignant transformation of a B lymphocyte in the outer
edge of a lymph node follicle, called the mantle zone and
resulting in lymph node (LN) enlargement. MCL accounts
for about 6% (∼3500) of all new NHL cases in the United
States each year and has the worst prognosis, with average
age at diagnosis in mid-60s. MCL is characterized by
overexpressionofcyclinD1(ccnd1),whichisusuallybecause
of a reciprocal translocation, t(11;14)(q13;q32). Like other6 Advances in Hematology
B-cell lymphomas, MCL is treated with a multidrug therapy
involving Bortezomib or autologous stem cell transplant.
Several miRNAs have been implicated in MCL patho-
genesis. miRNA expression proﬁling of B cells from MCL
patients led to 15 up- and 18 downregulated miRNAs. miR-
29 family (miR-29a, miR-29b,a n dmiR-29c) was among the
major downregulated miRs in addition to miR-142-3p/5p,
miR-150,a n dmiR-15a/b, and associated with short overall
survival [54]. Among the upregulated miRNAs were miR-
124a, miR-155, miR-328, miR-326, miR-302c, miR-345, miR-
373∗,a n dmiR-210 [54]. They also showed that miR-29
targetsCDK6,expression ofwhichisaknownprognosticand
pathogenetic factor in MCL. Furthermore, downregulation
of miR-29 is in line with the ccnd1 overexpression and the
consequent CDK4/CDK6 activation, which is the primary
event in MCL pathogenesis. The patients with signiﬁcantly
downregulated miR-29 had a shorter survival compared with
those who expressed relatively high levels of miR-29 [54].
Loss of miR-29a and miR-29c also correlates with TCL1A
overexpression in MCL, and direct regulation of it has been
previously shown [55].
According to another study, miR-31, miR-148a,a n dmiR-
27b were among the downregulated, and miR-617, miR-370,
and miR-654 were among the upregulated miRNAs in 23
MCL cases as compared to 11 reactive lymphoid tissues [57].
One of the predicted targets of miR-31 (most downregulated
miRNA) is MAP3K14 (NIK), a gene essential for activation
of the alternative NF-κBp a t h w a y[ 57]. Interestingly, the
miRNA clusters at locus 7q22 including miR-106b, miR-
93,a n dmiR-25 (overlapping miR-17∼92 cluster) were also
highly upregulated in MCL. Tumor suppressors targeted
by this cluster include PTEN, and the proapoptotic BIM
and miR-106b speciﬁcally promotes cell-cycle progression
by targeting cyclin-dependent kinase inhibitors p21/cdkn1a.
In addition, miR-106b overrides doxorubicin-induced DNA
damage checkpoint [60]. miR-20b, another member of the
oncomir-1 cluster,had a signiﬁcant clinicalprognostic value,
loss of which was associated with better prognosis in MCL
similar to several other diseases like gastric cancer, T-cell
leukemia, and mammary tumors [57].
2.2.3. Burkitt Lymphoma (BL). According to WHO classiﬁ-
cation, Burkitt lymphoma (BL) is a rare, highly aggressive
NHL composed of monomorphic medium-sized B cells
with multiple nucleoli and numerous mitotic ﬁgures and is
m o r ec o m m o ni nc h i l d r e nt h a ni na d u l t s[ 61]. The tumor
exhibits a starry-sky pattern because of the histiocytes with
phagocytosis of apoptotic cellular debris [62]. BL has been
referred to as “The Rosetta Stone of Cancer” because of the
many Firsts: ﬁrst human cancer shown to be associated with
virus, chromosomal translocation leading to activation of an
oncogene, and the ﬁrst cancer to be successfully treated with
chemotherapy alone [63].
Cytogenetically, almost all BL cases have a translocation
involving the MYC gene at 8q24 with the immunoglobulin
heavy chain gene (IGH) on 14q32 or less commonly with
kappa light chain locus (IGK) at 2q11 or light chain locus
(IGL) at 22q11 [26, 49] and the Epstein Bar Virus (EBV)
associated with most aggressive cases. Both, classic and
variant translocations involving MYC activation are associ-
ated with PVT1 oncogene, which encodes seven miRNAs
including hsa-miR-1204 responsible for c-myc activation
[66]. Robertus et al. (2010) recently showed myc-related
miRNA proﬁle that can characterizes Burkitt lymphoma
from other B-NHL (B-CLL, MCL & FL) [67]. Two of the
miRNAs downregulated in BL cell lines, EBV transformed
B-cell lines, CLL, and B cell lymphomas, are miR-143 and
miR-145, expression levels of which are inversely associated
with cell proliferation [68]. Moreover, miR-143 and miR-
145 are proposed to modulate MAPK signaling cascade via
downregulating ERK5, and other members of the pathway
to aﬀect cell growth and survival [68]. Expression analysis to
characterize various human B-cell stages and malignancies
derived from them yielded nineteen miRNAs which charac-
terized BL from other B-cell lymphomas (Table 2)[ 58].
2.2.4. Follicular Lymphoma/Indolent Lymphoma. Indolent
or slow growing NHL includes follicular lymphoma (FL),
tumor of germinal center origin, which accounts for 20–
30 percent of all NHL and usually takes several years to
develop. It has the tendency to transform into DLBCL,
with translocation t(14;18)(q23;q21) in 90% of cases and
is associated with BCL2 activation which may lead to accu-
mulation of GCB cells with prolonged lifespan. In addition,
this transformation may lead to c-myc gene rearrangement,
p53 or BCL6 mutation, or inactivation of tumor suppressors
p15 or p16 [69]. Comparative miRNA expression analysis of
46 FL cases to lymph node samples was used to generate
FL miRNA signature which included miRNAs which have
role in hematopoiesis (miR-150 and miR-155)o rt u m o r
development (miR-210, miR-10a, miR-17-5p,a n dmiR-145)
[51]. Few FL-speciﬁc miRNAs included miR-9/9∗, miR-301,
miR-338,a n dmiR-213 [51].
3.Rare Lymphomas
Among the rare lymphomas are the peripheral T-cell
lymphomas (PTCL) like enteropathy-associated T-cell lym-
phoma (EALT), gamma delta T-cell lymphoma, anaplastic
large cell lymphoma (ALCL), primary cutaneous PTCL,
and lymphocytic variant hypereosinophilic syndrome [59].
MiRNA expression proﬁling study of tumor cells (T-cell
clones) of a rare, aggressive, primary cutaneous T-cell
(CD4+) lymphoma called Sezary syndrome (SzS) showed
that majority of deregulated miRNAs were downregulated
including oncomir-1/miR-17-5p [59]. They further showed
thatectopicexpression ofmiR-17-5p increased apoptosisand
decreased cell proliferation in SzS cells [59]. Furthermore,
the four miRNA shaving a signiﬁcant diagnostic potential
(100% accuracy) for SzS included miR-150, miR-191, miR-
15a,a n dmiR-16. O t h e rm i R N A sw h i c hc o u l da l s od i s -
tinguish SzS samples from healthy controls with 96% of
accuracy were miR-223 and miR-17-5p [59]. Ballabio et al.
[59] also showed that direct targeting of EVL which is the
hostgeneofmiR-342,bytheupregulatedmiRNA,miR-199a∗
was responsible for its downregulation. EVL gene has beenAdvances in Hematology 7
Table 2: Summary of up- and downregulated miRNA expression proﬁles in major types of lymphomas.
Lymphoma Studies Upregulated miRNAs Downregulated miRNAs Reference
Diﬀuse large
B-cell
lymphoma
DLBCL (n = 59 primary;
n = 27 cell lines) See reference See reference [49]
DLBCL (n = 98 primary tumor;
n = 12 normal lymphocyte
population)
hsa-miR-100, hsa-miR-10b,
hsa-miR-125b, hsa-miR-143,
hsa-miR-145, hsa-miR-155,
hsa-miR-21, hsa-miR-34a,
hsa-miR-451, hsa-miR-9
hsa-miR-150, hsa-miR-181a,
hsa-miR-189, hsa-miR-223,
hsa-miR-361, hsa-miR-363,
hsa-miR-495, hsa-miR-584,
hsa-miR-625, hsa-miR-768-5p
[56]
DLBCL (n = 58)v e r s u sL N
(n = 7)
hsa-miR-210, hsa-miR-155,
hsa-miR-106a, hsa-miR-17-5p
hsa-miR-150, hsa-miR-145,
hsa-miR-328, hsa-miR-139,
hsa-miR-99a, hsa-miR-10a,
hsa-miR-95, hsa-miR-149,
hsa-miR-320, hsa-miR-151,
hsa-miR-let-7e
[51]
Follicular
lymphoma FL (n = 46)v e r s u sL N(n = 7)
hsa-miR-9, hsa-miR-9∗,
hsa-miR-301, hsa-miR-213,
hsa-miR-330, hsa-miR-106a,
hsa-miR-338, hsa-miR-155,
hsa-miR-210
hsa-miR-320, hsa-miR-149,
hsa-miR-139
[51]
Mantle cell
lymphoma MCL (n = 30)
hsa-miR-124a, hsa-miR-155,
hsa-miR-328, hsa-miR-326,
hsa-miR-302c, hsa-miR-345,
hsa-miR-373∗,a n dhsa-miR-210
hsa-miR-29a/b/c,
hsa-miR-142-3p/5p,
hsa-miR-150,a n dhsa-miR-15a/b
[54]
Burkitt
lymphoma
BL (n = 10)v e r s u sC L L
hsa-miR-130b, hsa-miR-154,
hsa-miR-155, hsa-miR-29b,
hsa-miR-29c, hsa-miR-637,
hsa-miR-658, hsa-miR-193a-5p,
hsa-miR-886-5p,
hsa-miR-768-5p, hsa-miR-101,
hsa-miR-933, hsa-miR-371-5p,
hsa-miR-675, hsa-miR-150,
hsa-miR-874, hsa-miR-181a,
hsa-miR-30c,
ebv-hsa-miR-BHRF1-2,
hsa-miR-628-3p
[58]
cMyc + BL (n = 10)
versus cMyc − BL ( n = 9) hsa-miR-17-5p, hsa-miR-20a hsa-miR-9∗, hsa-miR-34b [64]
Hodgkin
lymphoma
cHL (n = 3, cell lines)
hsa-miR-17∼92, hsa-miR-16,
hsa-miR-15, hsa-miR-21,
hsa-miR-24 and hsa-miR-155
hsa-miR-150 [39]
HL/HRS cell versus GC B cells
hsa-miR-20a, hsa-miR-21,
hsa-miR-9, hsa-miR-155,
hsa-miR-16, hsa-miR-140,
hsa-miR-18a, hsa-miR-30b,
hsa-miR-30a-5p, hsa-miR-196a,
hsa-miR-374, hsa-miR-186
hsa-miR-520a, hsa-miR-200a and
hsa-miR-614
[36]
cHL (primary, n = 49) hsa-miR-96, hsa-miR-128a,
hsa-miR-128b
[38]
HL cell lines (n = 3, L-428 &
HD-MY-Z, L-1236)
hsa-miR-34a, hsa-miR-128b,
hsa-miR-129, hsa-miR-200a
hsa-miR-122a, hsa-miR-154,
hsa-miR-302d, hsa-miR-371
[38]
cHL cell lines
hsa-miR-21, hsa-miR-27a,
hsa-miR-147, hsa-miR-182,
hsa-miR-183, hsa-miR-216
hsa-miR-126, hsa-miR-135a,
hsa-miR-204
[38]
EBV + versus EBV − cHL
hsa-miR-28, hsa-miR-130b,
hsa-miR-132, hsa-miR-140,
hsa-miR-330
hsa-miR-96, hsa-miR-128a,
hsa-miR-128b, hsa-miR-129,
hsa-miR-205
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Table 2: Continued.
Lymphoma Studies Upregulated miRNAs Downregulated miRNAs Reference
T-cell
lymphoma
Sezary syndrome/SzS (n = 17)
hsa-miR-145, hsa-miR-574-5p,
hsa-miR-200c, hsa-miR-199a∗,
hsa-miR-143, hsa-miR-214,
hsa-miR-98, hsa-miR-518a-3p,
hsa-miR-7
hsa-miR-342, hsa-miR-223,
hsa-miR-150, hsa-miR-189(24∗),
hsa-miR-186, hsa-miR-423-3p,
hsa-miR-92, hsa-miR-181a,
hsa-miR-191, hsa-miR-376a
[59]
Lymphocyte variant
Hypereosinophilic
syndrome/L-HES (n = 7)
Let-7b, hsa-miR-221,
hsa-miR-222,
hsa-miR-26a, hsa-miR-31,
hsa-miR-95, hsa-miR-99a,
hsa-miR-100, hsa-miR-126,
hsa-miR-130a, hsa-miR-135b,
hsa-miR-135a, hsa-miR-151,
hsa-miR-181a, hsa-miR-181b,
hsa-miR-193a, hsa-miR-213,
hsa-miR-215, hsa-miR-335,
hsa-miR-340, hsa-miR-125a
[65]
implicated in carciongenesis of colorectal cancers where it is
silenced by CPG methylation. Out of the 114 diﬀerentially
expressed miRNAs, the only 10 upregulated miRNAs in SzS
samples were miR-145, miR-574-5p, miR-200c, miR-199a∗,
miR-143, miR-214, miR-98, miR-518a-3p,a n dmiR-7.T h e
aberrant expression of MYC in SzS was found to correlate
with the set of miRNAs including miR-30, miR-22, miR-
26a, miR-29c, miR-30, miR-146a,a n dmiR-150 which were
downregulated.
Another miRNA proﬁling study of a premalignant T-cell
clone in lymphocytic variant hypereosinophilic syndrome
(L-HES) unraveled a set of downregulated miRNAs which
arepredictedtotargetthethreeupregulatedmRNAs:RBBP8,
CLU, and MAP3K8. The retinoblastoma binding protein 8
gene (RBBP8) is a predicted target of miR-31, miR-126, miR-
130a,a n dmiR-335 and is a putative tumor suppressor. On
the other hand, Clusterin (CLU) is a predicted target of
miR-99a, miR-100, miR-126,a n dmiR-335 and is commonly
associated with tumorigenesis and malignant progression in
part through TGF-miR-135a, miR-135b, miR-181a,a n dmiR-
181b [65]. Another miRNA whose expression signiﬁcantly
decreases with the progression of L-HES to T lymphoma was
miR-125a. Accordingly, its predicted target genes, PTPRN2
(member of the receptor-type protein tyrosine phosphatase
family) and AHI1 (Abelson helper integration site 1), were
signiﬁcantly upregulated [65]. miR-125b (homolog of miR-
125a) has been shown to target TNFα and decrease cell
proliferation in mouse macrophage cells [70]. The exact role
of miR-125b is complicated by the fact that it is predicted to
target more tumor suppressors than oncogenes, and one of
the most important predicted candidates is the antiapoptotic
MCL1 (Myeloid cell leukemia 1), a gene frequently upreg-
ulated in CLL and myeloid leukemias. Further studies will
help understand its role in immune cell development and
lymphoma genesis.
4.PotentialformiRNAsinPrognosis and
OutcomePrediction
miRNA expression proﬁling studies have been successfully
used not only to diﬀerentiate normal from cancer tissues but
also to classify tumor types and grades. In addition, miRNA
expression proﬁling can also provide a unique miRNA
expression signature, which could be related to response to
therapy andsurvival through[38,58].Lietal.[49],Roehleet
al. [51], and others have successfully used miRNA expression
proﬁles to determine unique miRNA signatures, which can
classify lymphomas into categories with distinct treatment
response and outcome in the patients (Table 1). A recent
report by Lawrie et al. [71]s h o w e dmiR-21 serum levels
to be associated with relapse-free survival in patients with
DLBCL. Similarly, serum levels of miR-141 have been shown
to distinguish between prostate cancer patients and healthy
individuals [72]. In MCL, miR-20b expression is related
to poor survival, and its lack of expression distinguished
cases with a survival probability of 56% at 60 months [57].
One of the miRNAs consistently downregulated in most
lymphomas is miR-150, owing to its important role as tumor
suppressor as shown in a loss-of-function mouse model
[73]. Mice lacking miR-150 have increased expression of its
target transcription factor, c-Myb oncogene, which plays an
important role in lymphocyte development and maturation
[73]. Therefore, miRNA expression proﬁling provides a
useful tool for prognosis, diagnosis, and outcome prediction
in lymphoma patients.
5.TherapeuticPotentialsformiRNAs
inLymphomas
Since miRNA expression is deregulated in several lym-
phomas, and unique miRNA signatures have been identi-
ﬁed for prognosis and response to therapy, they become
quiet appealing as therapeutic targets. Common therapeutic
strategiesinvolveantisense-mediated inhibitionofoncogenic
miRNAs and miRNA mimetics or viral-vector encoded
overexpression of tumor suppressor miRNAs. Some of the
strategies in the former category involve oligonucleotides
with chemical modiﬁcations, liposomes, polymers, hydro-
gels, and nanoparticles [5]. Synthetic anti-miRNA oligonu-
cleotides (AMOs), which have 2-O-methyl modiﬁcation,
provide an eﬀective inhibition of miRNAs in cell culture and
xenograft mouse models but work only at high doses [74].Advances in Hematology 9
Targeting of miR-21 by 2-O-methyl AMOs in glioblastoma
and breast cancer has been achieved in vitro and xenograft
mice model, respectively [75, 76]. An alternative to AMOs
is locked nucleic acid- (LNA-) based anti-miRs, which have
been shown to be more stable and less toxic in inhibiting
endogenous miRNAs in vivo [77, 78]. Elm´ en et al. [78]
used LNA-antimiR for eﬃcient silencing of miR-122 in
primates, and a Phase 1 study is currently underway in
humans. Another strategy recently developed to inhibit
multiple miRNAs is called miR-sponge. miRNA sponges
are transcripts that contain multiple tandem binding sites
to speciﬁc miRNAs [79]. Sponge mRNA can be expressed
from stably integrated transgenes in vivo to silence the
target miRNAs and can perform comparable to antisense
oligonucleotides. In case of miRs which are encoded in
cluster, for example, miR-17∼92 family (and its paralogs,
together encoding 15 miRNAs), it will be more eﬃcient
to generate a transgenic mouse with miR-cluster sponge to
inhibit than deleting each miR individually [80].
On the other hand, restoration of tumor suppressor
miRNAscan be achievedby synthetic miRNA mimics, which
are usually double stranded and chemically modiﬁed (2 -O-
methyl with phosphorothioate modiﬁcations). Use of miR-
15a and miR-29 mimics in prostate and AML cell lines,
respectively, induced apoptosis [5, 81]. Another method
to increase expression of tumor suppressor miRNAs is
adenovirus-associated vectors (AAVs). AAV-mediated miR-
26 delivery into a murine model of liver cancer shows
promise for miR replacement therapy [82]. AAV-based
vectors do not integrate into the genome and are eliminated
eﬃciently with minimal toxicity as seen in Phase I and Phase
II clinical trials of about 200 patients [83, 84].
Other formulations like cationic lipids or liposomes,
polymers, and nanoparticles have recently become popular
to increase the eﬃciency of oligonucleotide uptake [5].
Liposomes consist of an aqueous compartment enclosed
by a phospholipid bilayer and form stabilized complexes
on electrostatic interactions with oligonucleotides [85]. In
the studies so far, liposomes have been shown to induce
hypersensitivereactionsowingtotoxicity,andhenceresearch
eﬀorts to maximize their beneﬁts are underway [86]. Poly-
mers and nanoparticles on the other hand are promising
because they provide improved delivery and stability with
minimal in vivo toxicity [5, 87].
6. FutureDirections
From the past and ongoing work on miRNAsin lymphomas,
it is evident that deregulation of miRNA expression is one
of the critical steps in pathogenesis of several lymphomas.
Similar to mRNA, miRNA expression proﬁling can success-
fullyclassifyvariouslymphomasintotherapeuticoutcomeor
survival categories. Identiﬁcation of novel miRNA genes by
new technologies like deep sequencing can further enhance
the scope of miRNA functions and therapeutic applications
[88]. In order to better understand the role of miRNAs in
various lymphomas, future work should involve studying
the targets involved in lymphomas and understand the
mechanisms associated with them. In addition, generation
of transgenic and knockout mouse models of lymphoma-
associated miRNAswill helpunderstand mechanisms under-
lying pathogenesis of these malignancies. Development of
miRNA-based therapeutics faces similar challenges such
as small interfering RNA therapeutics, potential oﬀ-target
eﬀects, safety, and mode of delivery (reviewed by Garzon et
al. [5]). Hence, Mouse models of gain and loss of function
of various miRNAs can be proved useful for respective miR-
inhibitor or mimic-based therapies. These experiments can
alsoleadtodevelopmentofoptimalformulationanddelivery
techniques.
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